INVENIS BIOTHERAPIES is an ilab 2022 winner


InVenis Biotherapies, a biotechnology start-up from Lille, France, which is developing
a regenerative medicine based on platelet lysate dedicated to the treatment of
various brain diseases, has won the ILAB 2022 competition. 

Amyotrophic Lateral Sclerosis (ALS or Charcot disease) is a rare neurodegenerative disease
that affects 250,000 people worldwide. ALS is a particularly severe disease
with a median survival of 3 years after diagnosis and is currently incurable.
The Invenis Biotherapies team is using the body's natural repair system
contained in blood platelets to develop a treatment for ALS. This project is
the result of more than ten years of academic and industrial research conducted
at University of Lille and Taipei Medical University by the teams of Prof. David
Devos and Prof. Thierry Burnouf and has already been the subject of numerous
international publications, patents and awards. 

"The blood platelets produced in the bone marrow are known for their role in
coagulation, but they also play an essential role in wound healing, tissue
regeneration and neuroprotection. To be able to use this immense and natural
potential to fight neuronal death is a great hope," according to Professor
Thierry Burnouf, Vice-Dean, College of Biomedical Engineering, Taipei Medical
University, Taiwan and co-founder of InVenis Biotherapies. 

"We hope to preserve the autonomy and quality of life of people with ALS and, in
the longer term, to be able to treat other neurodegenerative diseases such as
Alzheimer's or Parkinson's," said Prof. David Devos, University of Lille,
Neuroscience & Cognition, Inserm, UMR-S1172, CHU-Lille, France, and
co-founder of InVenis Biotherapies. 

InVenis Biotherapies aims to become as a world leader in regenerative medicine
and to offer a more effective alternative to stem cells in various fields.  

Thanks to the scientific excellence and quality of the project, Invenis Biotherapies now
benefits from the support of BPI FRANCE and can accelerate the development of
its biotherapeutic treatment.